The correlation between insulin resistance and AD’s pathology underscores the possibility that metabolic dysfunction may intensify neurodegenerative processes, indicating that modulating insulin signalling might provide therapeutic strategies for mitigating AD development (Kakoty et al. 2023; Salkovic-Petrisic et al. 2022). This evidence concerns the gene INS and Alzheimer disease.